Global shortage of radium-223 (Xofigo)

Apparently a problem in the manufacturing process for radium-223 dichoride (Xofigo) at the only plant where the drug is made (in Norway) has required that the plant be temporarily shut down. The supply of radium Ra-223 will run out tomorrow (October 10, 2014) for all current and new patients, worldwide. … READ MORE …

NICE fails to endorse treatment with radium-223 for mCRPC

In a less than entirely surprising move, the UK’s National Institute for Health and Care Excellence has rejected Bayer’s initial application for coverage of radium-223 (Xofigo) under the National Health Service. … READ MORE …

Bayer to acquire full ownership of radium-223

According to a report on the MarketWatch web site this morning, Bayer AG’s acquisition of Algeta will be completed before the end of March this year, at which time Bayer will become the sole owner of radium-223 (Xofigo) with full responsibility for the future development and marketing of this drug currently indicated for the treatment of late stage prostate cancer.

“Top pick” focuses on advances in treatment of mCRPC

In a new article on the Practice Update web site, Dr. Howard Scher, an oncologist specializing in treatment of advanced prostate cancer at Memorial Sloan-Kettering Cancer Center in New York, writes about his “top pick” regarding new prostate cancer knowledge from 2013. … READ MORE …

EC gives marketing approval for radium-223 in metastatic CRPC

We understand that, earlier today, the European Commission (EC) approved radium-223 dichloride (Xofigo®) for the treatment of men with castration-resistant prostate cancer (CRPC), symptomatic bone metastases, and no known visceral metastases. … READ MORE …

Final data on radium-223 in mCRPC published in NEJM

The final results of the Phase III randomized clinical trial of radium-223 in treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) have just been published in the New England Journal of Medicine this morning. … READ MORE …

US FDA approves radium-223 dichloride for treatment of men with mCRPC

The “New” Prostate Cancer InfoLink apologizes for a delay in letting readers know that on Wednesday the US Food & Drug Administration approved radium-223 dichloride (Xofigo®) for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases, but no known visceral (i.e., soft tissue) metastases. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,154 other followers